On Monday, Horizon Pharma PLC (NASDAQ:HZNP)’s shares declined -1.57% to $31.92.
Horizon Pharma PLC (HZNP) declared its first quarter 2015 financial results.
First Quarter 2015 Financial Results
Total net sales in the first quarter of 2015 were $113.1 million, contrast with $51.9 million in the first quarter of 2014, and representing 118 percent growth.
- Gross margins were 74 percent in the first quarter of 2015 contrast with 85 percent in the first quarter of 2014. On an Adjusted non-GAAP basis, gross margins were 91 percent in the first quarter of 2015 and 89 percent in the first quarter of 2014, not taking into account depreciation, intangible amortization, amortization of inventory step-up and royalty accretion, but counting royalties incurred during the quarter based on that period’s net sales for VIMOVO and ACTIMMUNE.
- Total operating expenses were $79.5 million in the first quarter of 2015, contrast to $42.7 million in the first quarter of 2014. The enhance in operating expenses reflects the enhances in research and development expenses, principally related to ACTIMMUNE, sales and marketing expenses primarily due to the expansion of our sales force for PENNSAID 2% together with other costs related to ACTIMMUNE and PENNSAID 2% and general and administrative expenses, principally due to the build out of infrastructure to support the Company’s growth. First quarter 2015 operating expenses comprised of $3.7 million of transaction-related expenses associated with the acquisitions of Vidara Therapeutics International plc, or Vidara, and Hyperion Therapeutics, Inc., or Hyperion.
Horizon Pharma plc, a specialty biopharmaceutical company, engages in identifying, developing, acquiring or in-licensing, and commercializing medicines for the treatment of arthritis, pain, inflammatory, and/or orphan diseases in the United States and internationally.
Amgen, Inc. (NASDAQ:AMGN)’s shares gained 0.49% to $157.03.
Amgen, Inc. (AMGN) declared a partnershipwith Roche on a Phase 1b study to evaluate the safety and efficacy of talimogene laherparepvec, Amgen’s investigational oncolytic immunotherapy, in combination with Roche’s investigational anti-PDL1 therapy, atezolizumab (also known as MPDL3280A), in patients with triple-negative breast cancer and colorectal cancer with liver metastases.
Talimogene laherparepvec is an investigational oncolytic immunotherapy designed to selectively replicate in tumors (but not normal tissue) and to initiate an immune response to target cancer cells. Atezolizumab is an investigational monoclonal antibody designed to interfere with the PD-L1 protein.
The rationale for combining these two investigational agents is to activate an anti-tumor immune response with talimogene laherparepvec and to block inhibitory T cell checkpoints with atezolizumab, to potentially enhance the anti-tumor activity relative to each agent alone.
Amgen Inc., a biotechnology company, discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses for the treatment of illness in the areas of oncology, hematology, inflammation, bone health, nephrology, cardiovascular, and general medicine.
At the end of Monday’s trade, Kohl’s Corporation (NYSE:KSS)‘s shares dipped -1.22% to $64.69.
Kohl’s Corporation (KSS) declared their partnership with Kohl’s Thank You Thursday, offering free general admission to the Museum on the first Thursday of every month. Kohl’s Thank You Thursday marks the first time ever free general admission has been regularly offered to the public and will kick off on Thursday, June 4.
Kohl’s Corporation operates department stores in the United States. It offers private label, exclusive, and national brand apparel, footwear, accessories, beauty, and home products to children, men, and women customers. The company also sells its products online at Kohls.com and through mobile devices.
United Parcel Service, Inc. (NYSE:UPS), ended its Monday’s trading session with 0.26% gain, and closed at $99.48.
United Parcel Service, Inc. (UPS) declared it will donate over $10 million to non-profit,non-governmental and United Nations agencies organizations in 2015for the purpose of increasing community safety around the world. Focus areas for donations comprise emergency preparedness, disaster relief response/recovery and road safety.
In 2014, the UPS Humanitarian Relief & Resilience program offered global relief partners with funds, in-kind support and supply chain expertise to support preparedness, emergency response and recovery capabilities. UPS offered staging capacity for relief items to the World Food Program (WFP), the Centers for Disease Control and Prevention, Inc.(CDC), and other partners, to assist the humanitarian relief community respond to the Ebola epidemic. UP also assisted address the needs of displaced refugees by transporting hundreds of thousands of winter supplies to Syrian refugees, and by leveraging UPS technologies to strengthen distribution tracking of food and vital supplies for the United Nations High Commissioner for Refugees (UNHCR).
United Parcel Service, Inc., a package delivery company, provides transportation, logistics, and financial services in the United States and internationally. It operates in three segments: U.S. Domestic Package, International Package, and Supply Chain & Freight. The U.S. Domestic Package segment offers time-definite delivery of letters, documents, small packages, and palletized freight through air and ground services in the United States.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
